We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · November 23, 2021

Impact of Checkpoint Inhibitor Immunotherapy on Infection Risk in Advanced Lung Cancer

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study
Clin. Infect. Dis. 2021 Nov 02;73(9)e2697-e2704, AE Malek, M Khalil, R Hachem, AM Chaftari, J Fares, Y Jiang, DP Kontoyiannis, F Fossella, P Chaftari, VE Mulanovich, GM Viola, II Raad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading